Prana Thoracic Announces Series A Financing
Prana Thoracic, Inc. (“Prana” or the “Company”), a medical device company developing the first minimally invasive lung tissue excision tool for early intervention in lung cancer, has announced the closing of a $3 million founding Series A financing led by New World Angels.
- Prana Thoracic, Inc. (“Prana” or the “Company”), a medical device company developing the first minimally invasive lung tissue excision tool for early intervention in lung cancer, has announced the closing of a $3 million founding Series A financing led by New World Angels.
- The Series A funds and a previously announced $3M award from the Cancer Prevention & Research Institute of Texas will be used for product development and to support the Company’s first-in-human clinical studies.
- “Our technology provides a definitive answer to patients with lung nodules and allows physicians to intervene earlier in the lung cancer patient’s journey,” said Joanna Nathan, CEO, and co-founder of Prana.
- Prana’s technology was developed on the Texas Medical Center campus, in collaboration with Precision Thoracic Corporation.